Follow The Filings

CTSO Cytosorbents

Cytosorbents earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by CTSO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CTSO insider trades
  • $269K bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Phillip P. Chan CEO
    Buy
    $23K 3,774 shares at $6.00 +3.9% to stake
    Traded Sep 15 Filed Sep 16
  2. Vincent Capponi COO
    Buy
    $13K 2,073 shares at $6.05 +5.4% to stake
    Traded Sep 14 Filed Sep 16
  3. Alan D. Sobel Director
    Buy
    $15K 2,500 shares at $6.10 +34% to stake
    Traded Sep 15 Filed Sep 16
  4. Phillip P. Chan CEO
    Buy
    $70K 200,000 shares at $0.3500 +12% to stake
    Traded Sep 4 Filed Sep 9
  5. Peter J Mariani CFO
    Buy
    $44K 100,000 shares at $0.4400 +19% to stake
    Traded Jun 15 Filed Jun 16
  6. Phillip P. Chan CEO
    Buy
    $105K 261,469 shares at $0.4000 +18% to stake
    Traded Jun 12–15 Filed Jun 15

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01
8-K 5.03,9.01
8-K 5.07
8-K 7.01,9.01
10-Q
8-K 2.02,9.01
8-K 3.01
DEF 14A FORM DEF 14A
8-K 7.01,9.01
DEFA14A
8-K 2.02,9.01
10-Q
10-K/A
8-K 3.01
10-K
8-K 2.02,7.01,9.01
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
8-K 3.01
8-K 7.01,8.01,9.01
8-K 8.01,9.01
10-Q
8-K 2.01,9.01
8-K 8.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.